Regenerative Medical Technology Group Inc.
Regenerative Medical Technology Group Inc. is a U.S.-based regenerative medicine company centered on stem cell-related products, clinical services, practitioner education, and manufacturing support. Its business combines direct patient treatments, product commercialization, training programs, and clinic-network operations across international markets.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaCell therapy kits, exosome therapies, peptides, biologics, and related consumables sold to clinics and practitioners.
Direct patient care and treatment procedures delivered through company-operated or affiliated clinics.
Training, seminars, congresses, and practitioner certification through the ISSCA platform.
Logistics, inventory management, technical support, and sales training for external partners and clinics.
Manufacturing scale-up and product development for new regenerative medicine formulations.
Tuotteet
Raportoitu · osuus liikevaihdosta- Product Supplies39,7 %
- Patient Procedures36,8 %
- Training22,1 %
- Equipments1,5 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
The company sells to medical practitioners, clinics, and external distribution partners that use or resell regenerative medicine products. It also serves patients directly through clinic-based treatment services, while its education platform targets doctors and clinical staff seeking training and certification in stem cell applications.
Buy stem cell kits, products, equipment, and training to deliver regenerative medicine protocols.
Patients receiving treatments at company clinics, generating service revenue and product pull-through.
Qualified partners that market and distribute the company's products in their territories.
Practitioners and institutions that attend ISSCA programs, seminars, and certification courses.
Universities and clinical organizations engaged for protocol development and validation.
Strategia
The company is building a vertically integrated regenerative medicine platform that combines product development, manufacturing, education, and clinical delivery. Its strategy emphasizes clinic-network expansion, broader distribution, new product formulations, and partnerships with medical institutions to support market entry and practitioner adoption.
Direct patient care adds recurring revenue and creates demand for the company's products.
Greater production capacity supports product availability, quality control, and vertical integration.
New formulations broaden the addressable market and reduce reliance on a narrow product set.
Training and certification support practitioner adoption and reinforce the company's protocol ecosystem.
The U.S. offers a large market but requires careful regulatory navigation and clinical credibility.
Maantiede
The company operates internationally, with clinical and distribution activity spanning the Americas, the Middle East, and other global markets. Reported operations include clinics in Cancun, Mexico and Dubai, with planned expansion into Puerto Rico, Argentina, Saudi Arabia, and the United States.
Riskit
The business depends on regulatory acceptance of regenerative medicine, clinical adoption, and the ability to fund expansion and working capital needs. It also faces execution risk from manufacturing scale-up, clinic launches, and the need to maintain quality, compliance, and practitioner trust across multiple jurisdictions.
The company states it will require additional funding to finance growth and strategic objectives.
Kohdistuu: Corporate-wide
Clinical use of stem cell and related therapies depends on evolving rules and approvals in each market.
New clinics require local infrastructure, staffing, compliance, and patient demand to succeed.
Scaling production across locations can affect product consistency and regulatory compliance.
Kohdistuu: Manufacturing footprint
Patient-facing regenerative therapies are sensitive to safety, efficacy, and practitioner trust.
Kohdistuu: Clinic network and education platform
Kirjanpito
Harkinnanvaraiset erätRevenue is recognized when products transfer or services are performed, affecting timing across clinics and product sales.
Vaikutus: Product shipments and treatment sessions may be recognized in different periods
The company references business combinations and goodwill estimates, which can require impairment testing.
Vaikutus: Could create non-cash charges if acquired value declines
The company discloses derivative instruments and fair value estimates, which can move earnings without cash impact.
Vaikutus: May introduce volatility in reported results
Additional funding is required to support operations and expansion, making liquidity assumptions important.
Vaikutus: Affects balance sheet presentation and investor risk assessment
Valuation of preferred stock, assets, and liabilities depends on management assumptions.
Vaikutus: Can materially affect reported equity and expenses
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Harvard Apparatus Regenerative Technology, Inc.
HRGN · Surgical & Medical Instruments & Apparatus
Organogenesis Holdings Inc.
ORGO · Pharmaceutical Preparations
BioRestorative Therapies, Inc.
BRTX · Services-Misc Health & Allied Services, NEC
International Stem Cell CORP
ISCO · Pharmaceutical Preparations
RetinalGenix Technologies Inc.
RTGN · Surgical & Medical Instruments & Apparatus
Metagenomi Therapeutics, Inc.
MGX · Biological Products, (No Diagnostic Substances)
Päivitetty: 24.9.2026